Clinical trials: Pharmacogenetic Testing
Perioperative/Postoperative Complications
Prospective Study to Evaluate the Clinical Utility of Perioperative Pharmacogenomic Testing
In the perioperative realm, studies have demonstrated an association of genotype with efficacy of medications applicable to the surgical setting.
- Trial name
- NCT03531268
- Testing
- PGx Testing
- Where
- 2 sites in United States
- Sponsor
- Brigham and Women's Hospital
HIV/AIDS, Nicotine Dependence
Optimizing Tobacco Use Treatment for PLWHA
The advent of anti-retroviral therapy (ART) for people living with HIV/AIDS (PLWHA) substantially improved life expectancy but has also led to the critical need to address modifiable risk factors associated with cancer and…
- Trial name
- HTO (NCT04176172)
- Testing
- Varenicline, Nicotine patch, Standard treatment
- Where
- 2 sites in United States
- Volunteers
- 340 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pharmacogenetics, Pharmacogenomic Drug Interaction
An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.
The goal of this prospective randomized clinical trial is to learn if a pharmacist-provided personalized medication review (PMR) that discusses pharmacogenomic test results will improve medication outcomes.
- Trial name
- MyPGx (NCT06660264)
- Testing
- Pharmacist Personalized Medication Review (PMR), Discussion of Pharmacogenomic results during the PMR
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- University of Pittsburgh
Adverse Drug Reaction, Therapy Failure
Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Genetic makeup of a patient influences the efficacy and safety profile of a drug. This study is to summarize individual cases, where Pharmacogenetics (PGx) has been applied during pharmaceutical care.
- Trial name
- NCT04154553
- Testing
- Buccal swab, EDTA Blood sample (4.9mL), Serum sample (7.5mL)
- Where
- Switzerland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Tuberculosis Infection, Isoniazid Adverse Reaction
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
This trial is designed to determine whether modifying the dose of isoniazid for individuals according to their n-acetyltransferase 2 (NAT2) genotype could increase the probability of achieving equivalence of area-under-the-curve.
- Trial name
- NCT05413551
- Testing
- Low-dose isoniazid, Standard dose of isoniazid, High-dose isoniazid
- Where
- Brazil
- Volunteers
- 78 people
- Sponsor
- Stanford University
Chronic Pain
Pharmacogenetic Testing and Chronic Pain
Understanding the impact of genetics could aid rational, precision drug choices. In the current study, investigators will focus on whether genetic analysis of drug processing using the Inagene platform could predict efficacy and…
- Trial name
- NCT05259865
- Testing
- Genetic test for drug response prediction
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- Canadian Forces Health Services Centre Ottawa
Anemia, Cardiovascular Disease
An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial
The purpose of Study 20060172 was to measure echocardiographic parameters and biomarkers in a subgroup of study subjects enrolled in Study 20050222 (the RED-HF Trial).
- Conditions
- Anemia, Cardiovascular Disease, Congestive Heart Failure, Heart Failure
- Trial name
- NCT00534456
- Testing
- Darbepoetin alfa
- Volunteers
- 12 people
- Sponsor
- Amgen
Breast Neoplasms, Tamoxifen
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer
This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast…
- Trial name
- MHSLabCorp1 (NCT00830973)
- Testing
- Poor Metabolism Status Follow Up Therapy Considerations, CYP2D6 Inhibiting Drugs
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Medco Health Solutions, Inc.